Loading insider details...
Beta
Latest Form 4 (Jun 11, 2026): Grant/Award of 30,000 DSGN shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Design Therapeutics, Inc. (DSGN) | Grant/Award | 30,000 | n/a |
| Jun 4, 2026 | Xenon Pharmaceuticals Inc. (XENE) | Exercise/Conversion | 2,645 | n/a |
| May 29, 2026 | COMPASS Pathways plc (CMPS) | Grant/Award | 21,110 | n/a |
| Jan 5, 2026 | Design Therapeutics, Inc. (DSGN) | Grant/Award | 45,000 | n/a |
| Sep 10, 2025 | Design Therapeutics, Inc. (DSGN) | Grant/Award | 30,000 | n/a |
| Jul 30, 2025 | COMPASS Pathways plc (CMPS) | Grant/Award | 52,000 | n/a |
| Jun 6, 2025 | Xenon Pharmaceuticals Inc. (XENE) | Grant/Award | 17,012 | n/a |
| Jun 5, 2024 | Xenon Pharmaceuticals Inc. (XENE) | Grant/Award | 15,542 | n/a |
| Aug 10, 2023 | Xenon Pharmaceuticals Inc. (XENE) | Grant/Award | 28,000 | n/a |